Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same
 haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension.
 The hyperventilation syndrome is a frequent cause of dyspnea in general population and in
 respiratory diseases like asthma but has never been studied in pulmonary hypertension. The
 goal of this study is to measure the prevalence of pulmonary hypertension in a population of
 patients with controlled pulmonary arterial hypertension (PAH).
Hyperventilation syndrome has been described as a cause of dyspnea in the general population
 and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics
 affected. However, Hyperventilation syndrome has never been sought in a population with PAH.
 Hyperventilation syndrome, although complex pathophysiology, may be simply corrected by a
 management of respiratory physiotherapy based on the control of respiration.
Inclusion Criteria:

 -  Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. -
 Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary
 hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4
 months.

 -  Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP
 < 300ng/L or Brain Natriuretic Peptide(BNP) < 50 ng/L and optimal hemodynamic results
 measured by a right heart catheterization in the last year: right atrial pressure < 8
 mmHg, cardiac index > 2,5 L/min/m2, veinous saturation in oxygen > 65%)

 -  Informed and written consent

 -  Non-affiliation to a social security

 Exclusion Criteria:

 -  Existence of another form of pulmonary hypertension

 -  Existence of vocal cord dysfunction

 -  Pregnancy

 -  Obesity> stage 2 (BMI 35 kg / m2)

 -  Age ≥ 75 years